206 related articles for article (PubMed ID: 27189278)
1. Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.
Kim WT; Yun SJ; Yan C; Jeong P; Kim YH; Lee IS; Kang HW; Park S; Moon SK; Choi YH; Choi YD; Kim IY; Kim J; Kim WJ
Yonsei Med J; 2016 Jul; 57(4):865-71. PubMed ID: 27189278
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the urinary metabolic variations and the application in bladder cancer biomarker discovery.
Liu X; Cheng X; Liu X; He L; Zhang W; Wang Y; Sun W; Ji Z
Int J Cancer; 2018 Jul; 143(2):408-418. PubMed ID: 29451296
[TBL] [Abstract][Full Text] [Related]
3. Integrative Pathway Analysis of Metabolic Signature in Bladder Cancer: A Linkage to The Cancer Genome Atlas Project and Prediction of Survival.
von Rundstedt FC; Rajapakshe K; Ma J; Arnold JM; Gohlke J; Putluri V; Krishnapuram R; Piyarathna DB; Lotan Y; Gödde D; Roth S; Störkel S; Levitt JM; Michailidis G; Sreekumar A; Lerner SP; Coarfa C; Putluri N
J Urol; 2016 Jun; 195(6):1911-9. PubMed ID: 26802582
[TBL] [Abstract][Full Text] [Related]
4. Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Yang C; Sun X; Wang H; Lu T; Wu K; Guan Y; Tang J; Liang J; Sun R; Guo Z; Zheng S; Wu X; Jiang H; Jiang X; Zhong B; Niu X; Sun S; Wang X; Chen M; Fu G
Int J Mol Med; 2019 Nov; 44(5):1952-1962. PubMed ID: 31545404
[TBL] [Abstract][Full Text] [Related]
5. Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.
Le Goux C; Damotte D; Vacher S; Sibony M; Delongchamps NB; Schnitzler A; Terris B; Zerbib M; Bieche I; Pignot G
Urol Oncol; 2017 May; 35(5):257-263. PubMed ID: 28291636
[TBL] [Abstract][Full Text] [Related]
6. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C
Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637
[TBL] [Abstract][Full Text] [Related]
7. Recognition of early and late stages of bladder cancer using metabolites and machine learning.
Kouznetsova VL; Kim E; Romm EL; Zhu A; Tsigelny IF
Metabolomics; 2019 Jun; 15(7):94. PubMed ID: 31222577
[TBL] [Abstract][Full Text] [Related]
8. Metabolic profiling analysis upon acylcarnitines in tissues of hepatocellular carcinoma revealed the inhibited carnitine shuttle system caused by the downregulated carnitine palmitoyltransferase 2.
Lu X; Zhang X; Zhang Y; Zhang K; Zhan C; Shi X; Li Y; Zhao J; Bai Y; Wang Y; Nie H; Li Y
Mol Carcinog; 2019 May; 58(5):749-759. PubMed ID: 30604893
[TBL] [Abstract][Full Text] [Related]
9. HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease.
Tripathi P; Somashekar BS; Ponnusamy M; Gursky A; Dailey S; Kunju P; Lee CT; Chinnaiyan AM; Rajendiran TM; Ramamoorthy A
J Proteome Res; 2013 Jul; 12(7):3519-28. PubMed ID: 23731241
[TBL] [Abstract][Full Text] [Related]
10. Indoleamine-2,3-dioxygenase-1 expression predicts poorer survival and up-regulates ZEB2 expression in human early stage bladder cancer.
Tsai YS; Jou YC; Tsai HT; Cheong IS; Tzai TS
Urol Oncol; 2019 Nov; 37(11):810.e17-810.e27. PubMed ID: 31253481
[TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
12. Frequent expression of zinc-finger protein ZNF165 in human urinary bladder transitional cell carcinoma.
Singh PK; Srivastava AK; Dalela D; Rath SK; Goel MM; Bhatt ML
Immunobiology; 2015 Jan; 220(1):68-73. PubMed ID: 25214475
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of thymosin β4 in the regulation of epithelial-mesenchymal transformation in urothelial carcinoma.
Wang ZY; Zeng FQ; Zhu ZH; Jiang GS; Lv L; Wan F; Dong R; Xiao XY; Xing SA
Urol Oncol; 2012; 30(2):167-76. PubMed ID: 20864366
[TBL] [Abstract][Full Text] [Related]
15. Differentiating progressive from nonprogressive T1 bladder cancer by gene expression profiling: applying RNA-sequencing analysis on archived specimens.
Sharron Lin X; Hu L; Sandy K; Correll M; Quackenbush J; Wu CL; Scott McDougal W
Urol Oncol; 2014 Apr; 32(3):327-36. PubMed ID: 24055427
[TBL] [Abstract][Full Text] [Related]
16. Urinary metabolomic signature of muscle-invasive bladder cancer: A multiplatform approach.
Jacyna J; Wawrzyniak R; Balayssac S; Gilard V; Malet-Martino M; Sawicka A; Kordalewska M; Nowicki Ł; Kurek E; Bulska E; Patejko M; Markuszewski M; Gutknecht P; Matuszewski M; Siebert J; Kaliszan R; Markuszewski MJ
Talanta; 2019 Sep; 202():572-579. PubMed ID: 31171223
[TBL] [Abstract][Full Text] [Related]
17. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
18. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers.
Shen C; Sun Z; Chen D; Su X; Jiang J; Li G; Lin B; Yan J
OMICS; 2015 Jan; 19(1):1-11. PubMed ID: 25562196
[TBL] [Abstract][Full Text] [Related]
19. lncRNA Up-Regulated in Nonmuscle Invasive Bladder Cancer Facilitates Tumor Growth and Acts as a Negative Prognostic Factor of Recurrence.
Zhang S; Zhong G; He W; Yu H; Huang J; Lin T
J Urol; 2016 Oct; 196(4):1270-8. PubMed ID: 27267320
[TBL] [Abstract][Full Text] [Related]
20. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients.
Pederzoli F; Ferrarese R; Amato V; Locatelli I; Alchera E; Lucianò R; Nebuloni M; Briganti A; Gallina A; Colombo R; Necchi A; Clementi M; Montorsi F; Mancini N; Salonia A; Alfano M
Eur Urol Oncol; 2020 Dec; 3(6):784-788. PubMed ID: 32345542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
